Here is a data-driven look at Dr. Reddy's Laboratories Ltd. (DRREDDY), covering financial performance, valuation, and shareholding trends.
Dr Reddy Revenue Trend
For FY2026, Dr. Reddy's Laboratories Ltd. recorded revenue of ₹33,700 Cr. That's 3.2% higher than the ₹32,644 Cr it brought in during FY2025.
The 10-year revenue CAGR of 7.9% reflects steady — if not spectacular — top-line expansion from ₹15,698 Cr to ₹33,700 Cr.
At ₹33,700 Cr in annual revenue, Dr. Reddy's Laboratories Ltd. is one of the major players in the pharmaceuticals space.
Dr. Reddy's Laboratories Ltd. has posted revenue growth for 9 consecutive years — that's a sustained trend, not a one-off.
| Year | Revenue | YoY % |
|---|---|---|
| FY2026 | ₹33,700 Cr | +3.2% |
| FY2025 | ₹32,644 Cr | +16.5% |
| FY2024 | ₹28,011 Cr | +13.5% |
| FY2023 | ₹24,670 Cr | +14.5% |
| FY2022 | ₹21,545 Cr | — |
View Dr. Reddy's Laboratories Ltd.'s full 10-year revenue trend with CAGR analysis →
Dr Reddy Profitability
Dr. Reddy's Laboratories Ltd. saw net profit contract 27.4% to ₹4,158 Cr in FY2026, down from ₹5,725 Cr in FY2025.
Net margin slipped from 17.5% to 12.3% in FY2026 — a sign of thinning profitability.
On an EPS basis, the company earned ₹50.35 (diluted) in FY2026 versus ₹67.79 in FY2025.
Is Dr Reddy Undervalued
Dr. Reddy's Laboratories Ltd. shares are currently trading at ₹1,180.00.
Craytheon calculates intrinsic value using the P/E Ratio, DCF, and EPS Growth models. All three appear in the Valuation Models cards below.
Valuation Models
Dr Reddy Shareholding Pattern
Promoter holding is steady at 26.6% — no buying or selling over the past 4 quarters.
The FII stake is at 32.1% as of June 2026, compared to 35.5% in the year-ago period.
On the domestic institutional side, the holding is 31.7% as of June 2026 — up from 28.0%.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Jun 2026 | 26.6% | 32.1% | 31.7% | 9.3% |
| Mar 2026 | 26.6% | 33.1% | 30.7% | 9.3% |
| Dec 2025 | 26.6% | 33.2% | 30.4% | 9.5% |
| Sep 2025 | 26.6% | 35.5% | 28.0% | 9.6% |
Track quarterly shareholding changes for Dr. Reddy's Laboratories Ltd. →
Dr Reddy Balance Sheet
Proportional view as of 3 Aug 2026. Hover blocks for details.
Assets
Liabilities & Equity
In FY2026, the total asset base came in at ₹581.23B, up 17.6% YoY from ₹494.27B.
Intangibles & Goodwill accounts for 20.6% of the total, ahead of Property, Plant & Equipment (19.9%) and Receivables (17.4%).
Capital structure: 65.8% equity, 13.3% debt, 20.9% operating liabilities. Over the year, debt is up 65.4% and equity is up 12.7%.
Balance sheet composition — FY 2026
| Category | Value |
|---|---|
| Cash & ST Investments | 53.60B |
| Receivables | 101.23B |
| Inventories | 76.53B |
| Property, Plant & Equipment | 115.38B |
| Investments | 14.62B |
| Intangibles & Goodwill | 119.86B |
| Other Assets | 100.02B |
| Category | Value |
|---|---|
| Equity | 382.31B |
| Short-term Debt | 65.14B |
| Long-term Debt | 12.20B |
| Trade Payables | 30.38B |
| Other Liabilities | 91.21B |
Dr Reddy Key Takeaways
Here's the bottom line on Dr. Reddy's Laboratories Ltd. (DRREDDY) based on the latest available financials.
Revenue of ₹33,700 Cr in FY2026, up 3.2% year-over-year.
Long-term revenue has been compounding at 7.9% annually over 10 years.
The company is profitable, with a net margin of 12.3% and net income of ₹4,158 Cr.
Unlock Full Analysis
See the full picture — Craytheon tracks 10 years of financial data with interactive charts, growth trends, and three valuation models for Dr. Reddy's Laboratories Ltd..